New liver drug AD-230 gets first human test – with or without food?

NCT ID NCT07618845

Not yet recruiting Knowledge-focused Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial will test a new drug called AD-230 in 24 healthy adults to see how food changes the way the body processes it. Participants will take the drug once after eating and once on an empty stomach. The goal is to gather safety and dosing information for future studies in people with chronic liver disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-230
What this could lead to: If successful, this study could help determine the best way to take AD-230 (with or without food) for future trials in people with chronic liver disease.
What could go wrong: This is a very early Phase 1 study in only 24 healthy volunteers, not patients. It is designed to measure safety and drug levels, not to treat disease. Many early-stage drugs fail to show benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE (CLD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LIVER DISEASE (CLD)

Contacts and locations

Locations

Kyungpook National university hospital

Daegu, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.